<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04009980</url>
  </required_header>
  <id_info>
    <org_study_id>RET04/2015</org_study_id>
    <nct_id>NCT04009980</nct_id>
  </id_info>
  <brief_title>Long-term Retinal Changes After Topical Citicoline Administration in Patients With Mild Signs of Diabetic Retinopathy in Type 1 Diabetes Mellitus.</brief_title>
  <official_title>Long-term Morphological and Functional Retinal Changes After Topical Citicoline Administration in Patients With Mild Signs of Diabetic Retinopathy in Type 1 Diabetes Mellitus: Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione G.B. Bietti, IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione G.B. Bietti, IRCCS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Citicoline (cytidine-5'-diphosphocholine) is an essential precursor in the synthesis of
      phosphatidylcholine, a component of cell membranes. Several experimental in vitro and in vivo
      studies have suggested that citicoline plays a neuroprotective role.

      A recent clinical study has shown that treatment with topical citicoline induces, after 60
      days of therapy, a significant improvement in the ganglion cell function .In addition topical
      citicoline has been demonstrated in vivo a neuroprotective effect in preventing diabetic
      retinopathy .

      The Investigators want to evaluate if citicoline may reduce the progression of retinal damage
      in patients with mild diabetic retinopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators evaluated patients with mild signs of diabetic retinopathy (DR) treated
      with eye-drop solution with citicoline ( OMk2 ophthalmic solution).

      All patients was randomized in two groups (10:10), one receiving topical administration of
      OMk2 ophthalmic solution for 36 months and one group receiving only the excipients of OMk2
      (placebo).

      Omk2 ophthalmic solution and the placebo will be used for 36 months three times/day.

      They will undergo a complete ocular examination at baseline and at 6-, 12-, 18-, 24-, 30- and
      36- months after treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 23, 2015</start_date>
  <completion_date type="Actual">June 7, 2019</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, interventional, randomized, double-masked, monocentric pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Retinal sensitivity and contrast sensitivity function after topical citicoline use in patients with diabetic retinopathy</measure>
    <time_frame>Functional retinal changes at 36 months</time_frame>
    <description>To evaluate functional retinal parameters : retinal sensitivity by Humphrey Matrix and contrast sensitivity function by Pelli Robson in patients with diabetic retinopathy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morphological retinal changes after topical citicoline use in patients with diabetic retinopathy</measure>
    <time_frame>Morphological retinal changes at 36 months</time_frame>
    <description>To evaluate morphological retinal parameters by Spectral Domain OCT( SD-OCT ) and by Adaptive Optics (AO) at each time point of follow up : retinal thickness, RNFL thickness, inner retinal thickness and outer retinal thickness.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>OMK2 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving topical administration of OMk2 ophthalmic solution for 36 months three times/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receiving receiving only the excipients of OMk2 (placebo) for 36 months three times/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OMK2 group</intervention_name>
    <description>topical administration of OMk2 ophthalmic solution for 36 months three times/day</description>
    <arm_group_label>OMK2 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo group</intervention_name>
    <description>topical administration of ophthalmic placebo solution for 36 months three times/day</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of type 1 DM

          -  Diagnosis of mild Diabetic rethnopathy (DR)

          -  Retinal sensitivity impairment evaluated by means of frequency doubling technology
             (Matrix FDT) with a mean deviation (MD) p value &lt;5% or with two locations with p &lt;5%
             and one location with p&lt;1% in the total or pattern deviation plots.

        Exclusion Criteria:

          -  Hyperopia higher than +5 diopter (D)

          -  myopia higher than -8 D

          -  astigmatism higher than 2 D

          -  Visual acuity below 20/25

          -  significant media opacity

          -  previous ocular surgery

          -  previous diagnosis of glaucoma

          -  uveitis

          -  retinal disease other than mild diabetic retinopathy

          -  patients with any ocular disease

          -  systemic disease other than diabetes

          -  Any signs of diabetic retinopathy more advanced than mild as coded by ICDRSS (e.g.
             macular edema or any sign of proliferative DR)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fondazione G.B.Bietti</name>
      <address>
        <city>Roma</city>
        <zip>00135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>van Dijk HW, Verbraak FD, Kok PH, Garvin MK, Sonka M, Lee K, Devries JH, Michels RP, van Velthoven ME, Schlingemann RO, Abràmoff MD. Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes. Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3660-5. doi: 10.1167/iovs.09-5041. Epub 2010 Feb 3.</citation>
    <PMID>20130282</PMID>
  </reference>
  <reference>
    <citation>Vujosevic S, Midena E. Retinal layers changes in human preclinical and early clinical diabetic retinopathy support early retinal neuronal and Müller cells alterations. J Diabetes Res. 2013;2013:905058. doi: 10.1155/2013/905058. Epub 2013 Jun 12.</citation>
    <PMID>23841106</PMID>
  </reference>
  <reference>
    <citation>Diederich K, Frauenknecht K, Minnerup J, Schneider BK, Schmidt A, Altach E, Eggert V, Sommer CJ, Schäbitz WR. Citicoline enhances neuroregenerative processes after experimental stroke in rats. Stroke. 2012 Jul;43(7):1931-40. doi: 10.1161/STROKEAHA.112.654806. Epub 2012 May 10. Erratum in: Stroke. 2012 Nov;43(11):e169.</citation>
    <PMID>22581817</PMID>
  </reference>
  <reference>
    <citation>Parisi V, Coppola G, Centofanti M, Oddone F, Angrisani AM, Ziccardi L, Ricci B, Quaranta L, Manni G. Evidence of the neuroprotective role of citicoline in glaucoma patients. Prog Brain Res. 2008;173:541-54. doi: 10.1016/S0079-6123(08)01137-0.</citation>
    <PMID>18929133</PMID>
  </reference>
  <reference>
    <citation>Parisi V, Manni G, Colacino G, Bucci MG. Cytidine-5'-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology. 1999 Jun;106(6):1126-34.</citation>
    <PMID>10366081</PMID>
  </reference>
  <reference>
    <citation>Roberti G, Tanga L, Parisi V, Sampalmieri M, Centofanti M, Manni G. A preliminary study of the neuroprotective role of citicoline eye drops in glaucomatous optic neuropathy. Indian J Ophthalmol. 2014 May;62(5):549-53. doi: 10.4103/0301-4738.133484.</citation>
    <PMID>24881599</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>July 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione G.B. Bietti, IRCCS</investigator_affiliation>
    <investigator_full_name>Mariacristina Parravano</investigator_full_name>
    <investigator_title>Head of Retina Unit</investigator_title>
  </responsible_party>
  <keyword>citicoline</keyword>
  <keyword>neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

